For the tumor stage, RHBDF2 overexpression was associated with unfavorable DSS in stage 1 HCC patients and related to bad OS and RFS in stage 3 HCC patients (Fig. 4A,C,D). Here, RHBDF2 is linked to hepatocellular carcinoma.